Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene ciloleucel with prophylactic steroids in relapsed/refractory large B-cell lymphoma (outpatient)
NCT05459571Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Aug 2022
- Primary completion
- Nov 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Kite Pharma. Started Aug 2022; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05459571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459571.